The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with ²²³Ra: first in human study.

ABSTRACT:

Background

²²³Ra is currently used for treatment of metastatic castration resistant prostate cancer patients (mCRPC) bone metastases with fixed standard activity. Individualized treatments, based on adsorbed dose (AD) in target and non-target tissue, are absolutely needed to optimize efficacy while reducing toxicity of α-emitter targeted therapy. This is a pilot first in human clinical trial aimed to correlate dosimetry, clinical response and biological side effects to personalize ²²³Ra treatment.

Methods

Out of 20 mCRPC patients who underwent standard ²²³Ra treatment and dosimetry, in a subset of 5 patients the AD to target and non-target tissues was correlated with clinical effects and radiation-induced chromosome damages. Before each

SUBMITTER: Sciuto R 

PROVIDER: S-EPMC8420003 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature